Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis

Non ancora tradotto Non ancora tradotto
Categoria Primary study
GiornaleJournal of Crohn's & colitis
Year 2016

This article is not included in any systematic review

This article is part of the following publication threads:
Loading references information

BACKGROUND AND AIMS:

This mediation modelling analysis evaluated direct and indirect effects of tofacitinib, an oral, small molecule Janus kinase inhibitor under investigation for ulcerative colitis, on patient treatment satisfaction.

METHODS:

Data from an 8‐week randomized Phase 2 trial [NCT00787202] in adults with moderate‐to‐severe, active ulcerative colitis receiving twice‐daily tofacitinib 0.5‐15mg [n=146] or placebo [n=48] were analysed in patient‐reported [n=149] and clinician‐reported [n=170] outcomes‐based mediation models. Binary predictor variable: Treatment [pooled active treatment vs placebo]. Eventual dependent variable: Week 8 patient treatment satisfaction [measured on a five‐point Likert scale]. Mediators of treatment effect on satisfaction: Week 8 Inflammatory Bowel Disease Questionnaire domains [Bowel Symptoms, Emotional Health, Social Function and Systemic Symptoms] and Mayo scale domains [Stool Frequency, Rectal Bleeding, Physician's Global Assessment and Endoscopic Disease Activity] for patient‐reported and clinician‐reported models, respectively.

RESULTS:

Overall tofacitinib indirect effect on satisfaction via Inflammatory Bowel Disease Questionnaire domains was 40.5% [p<0.05] and via Mayo scale domains was 84.0% [p<0.01] for patient‐reported and clinician‐reported models, respectively. Bowel function had the most important indirect effect: of the total tofacitinib effect on satisfaction, 32.4% [p=0.05] was indirectly mediated via Bowel Symptoms; and 30.0% [p=0.04] via Stool Frequency. In total, 59.5% [p<0.01] and only 16.0% [p=0.56] of tofacitinib's effect on satisfaction was unrelated to Inflammatory Bowel Disease Questionnaire and Mayo scale domains in the patient‐reported and clinician‐reported models, respectively.

CONCLUSIONS:

Bowel function is an important factor for patient treatment satisfaction with tofacitinib. Treatment effect on patient satisfaction was almost completely mediated via improvement in Mayo scale domains.
Epistemonikos ID: 102142d5ab25ac8b0163695c680fbf45b0ddc3e7
First added on: Mar 23, 2022